Swiss National Bank Purchases 94,300 Shares of Edwards Lifesciences Corporation $EW

Swiss National Bank increased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 5.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,703,100 shares of the medical research company’s stock after acquiring an additional 94,300 shares during the quarter. Swiss National Bank’s holdings in Edwards Lifesciences were worth $136,384,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $266,000. NewEdge Advisors LLC increased its holdings in Edwards Lifesciences by 8.1% during the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after buying an additional 2,665 shares during the period. Sei Investments Co. increased its holdings in Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after buying an additional 58,988 shares during the period. Squarepoint Ops LLC raised its stake in Edwards Lifesciences by 277.7% in the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after buying an additional 50,924 shares in the last quarter. Finally, Treasurer of the State of North Carolina raised its stake in Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after buying an additional 1,065 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.8%

EW stock opened at $85.05 on Tuesday. The firm has a 50 day moving average of $87.50 and a 200 day moving average of $83.91. The stock has a market capitalization of $48.97 billion, a PE ratio of 45.24, a price-to-earnings-growth ratio of 2.15 and a beta of 0.86. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the prior year, the business posted $0.64 EPS. Edwards Lifesciences’s revenue for the quarter was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $83.01, for a total transaction of $84,587.19. Following the completion of the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. This trade represents a 2.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 45,577 shares of company stock valued at $3,855,527. Company insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of several recent research reports. BTIG Research increased their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Evercore reissued an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. Citigroup upped their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Robert W. Baird raised their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Finally, Royal Bank Of Canada lifted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $98.95.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.